http://www.lsis.com/goto/r106/rss 2010-06-23T11:11:04+01:00 text/html http://www.marketwire.com Marketwire http://www.lsis.com/goto/v106/%3B%97f%FA%15%7Dxr BAGSVAERD, DENMARK-(Marketwire - June 22, 2010) - Novo Nordisk today announced the decision to re-initiate the global phase 3 development programme of liraglutide for the treatment of obesity. [HUG#1426038] Company Announcement no 32 2010: http:/hugin.info/2013/R/1426038/374101.pdf This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction for further distribution is prohibited. Source: Novo (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v106/%3B%97f%FB%10%7E%7B%7F BAGSVAERD, DENMARK-(Marketwire - 06/22/10) - Novo Nordisk today announced the decision to re-initiate the global phase 3 development programme of liraglutide for the treatment of obesity. Source: Novo Nordisk A/S via Thomson Reuters ONE text/html http://www.marketwire.com Marketwire http://www.lsis.com/goto/v106/%3B%97f%FB%10%7Dzx BAGSVà RD, DENMARK-(Marketwire - June 21, 2010) - [HUG#1425798] Company Announcement no 31 2010: http:/hugin.info/2013/R/1425798/373873.pdf This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction for further distribution is prohibited. Source: Novo Nordisk A/S via Thomson Reuters ONE text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v106/%3B%97f%FB%11%7By%7F BAGSVaeRD, DENMARK-(Marketwire - June 21, 2010) - [HUG#1425798] Company Announcement no 31 2010: http:/hugin.info/2013/R/1425798/373873.pdf This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction for further distribution is prohibited. Source: Novo Nordisk A/S via Thomson Reuters ONE Further information:Media: Investors:Anne Margrethe HaugeTel: (+45) 4442 6718Email ContactIn North (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v106/%3B%97f%FB%11zzy An article recently published in The Lancet reports that using an artificial pancreas system overnight can significantly reduce the risk of nocturnal hypoglycemia in children and adolescents with type 1 diabetes.(1) Moreover, the first clinical trial of an artificial pancreas system delivering both insulin and glucagon has shown that this system can prevent development of hypoglycemia.(2) The latest issue of the journal Diabetic Hypoglycemia reviews advances in artificial pancreas design and production in further detail. Dr Roman Hovorka, a leading artificial pancreas researcher and author of the Lancet paper(1) discusses developments in the field of closed-loop insulin delivery and (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v106/%3B%97f%FB%14%7E%7Dy SEATTLE-(BUSINESS WIRE)-ZymoGenetics, Inc. (NASDAQ:ZGEN) today announced that Lars Fruergaard Jørgensen of Novo Nordisk A/S was elected to the company s Board of Directors at the annual meeting of shareholders. He replaces Lars Rebien Sørensen, a previous Novo Nordisk representative, who resigned from the Board in March 2010. Novo Nordisk holds approximately 27% of the company s outstanding shares. We look forward to his participation and contribution in the coming years. "Lars Fruergaard Jørgensen brings to our Board many years of operational, financial and strategic experience in the global pharmaceutical industry," said Bruce L.A. Carter, Ph.D., Chairman of the Board of (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v106/%3B%97f%FB%14%7E%7Cz OTTAWA-(BUSINESS WIRE)-At its 2010 annual general meeting in Montreal yesterday, the national biotechnology association, BIOTECanada, confirmed a national team of industry leaders, whose expertise will ensure Canada keeps growing what today is an $84 billion bio-economy. As we face a new wave of technological innovation across agri-business and industrial and environmental biotechnologies, I am pleased to join this pan-Canadian group of industry leaders in raising awareness of the value our technologies bring to Canada s future The cross-sectoral team comes from companies across the country involved in industrial, agricultural, and health biotechnology including: crop DNA modification, (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v106/%3B%97f%FB%14%7E%7F%7D DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/d7d20e/discovery_stage_pa) has announced the addition of the "Discovery Stage Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, 2nd Edition" report to their offering. Discovery Stage Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, 2nd Edition The Discovery Stage Partnering Terms and Agreements in Pharma and Biotech report detailed understanding and analysis of how and why companies enter discovery stage licensing/business development and other forms of partnering arrangement. The report provides a detailed understanding and analysis of how and why companies enter (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v106/%3B%97f%FC%12%7B%7Bs SEATTLE-(BUSINESS WIRE)-ZymoGenetics, Inc. (NASDAQ:ZGEN) today announced that Lars Fruergaard Jørgensen of Novo Nordisk A/S was elected to the company s Board of Directors at the annual meeting of shareholders. He replaces Lars Rebien Sørensen, a previous Novo Nordisk representative, who resigned from the Board in March 2010. Novo Nordisk holds approximately 27% of the company s outstanding shares. text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v106/%3B%97f%FC%12%7E%7Dx DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/f119e5/diabetes_care_devi) has announced the addition of the "Diabetes Care Devices Market In Brazil, Russia, India & China (BRIC)" report to their offering. Diabetes Care Devices Market In Brazil, Russia, India & China (BRIC) This market research report analyzes the diabetes care devices market in Brazil, Russia, India, and China (BRIC) over the period 2009-2014. The report categorizes the overall market for diabetes care devices into the submarkets for insulin pumps, self-monitoring blood glucose systems, and continuous glucose monitoring systems. The diabetes care devices market in BRIC nations was (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v106/%3B%97f%FC%12%7D%7Cr DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/12ef8a/novo_nordisk_as) has announced the addition of the "Novo Nordisk A/S - SWOT Analysis" company profile to their offering. The Novo Nordisk A/S - SWOT Analysis company profile is the essential source for top-level company data and information. Novo Nordisk A/S - SWOT Analysis examines the company's key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy. Novo Nordisk is a healthcare company engaged in the manufacturing and marketing of diabetes products. It also offers product in the therapeutic areas of haemostasis (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v106/%3B%97f%FC%14%7D%7D%7C Summary. The aim of this study was to evaluate the in vitro function of the new recombinant factor VIII (FVIII) compound, N8. The specific activity of N8 as measured in a FVIII:C one-stage clot assay was 9300 +/- 400 IU mg(-1) based on the analysis of seven individual batches. The ratio between the FVIII:C activity measured in clot and chromogenic assays was 1.00 (95% confidence interval 0.97-1.03). N8 bound to von Willebrand factor with K(d) values of 0.2 nm when measured by ELISA and by surface plasmon resonance. FVIIIa cofactor activity was determined from the kinetic parameters of factor IXa-catalysed factor X (FX) activation. The rate of activation of N8 by thrombin as well as K(m) (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v106/%3B%97f%FC%15%7Fvx The glucagon-like peptide-1 (GLP-1) receptor is a key regulator of insulin secretion and a major therapeutic target for treatment of diabetes. However, GLP-1 receptor function is complex with multiple endogenous peptides that can interact with the receptor, including full length (1-37) and truncated (7-37) forms of GLP-1 that can each exist in an amidated form, and the related peptide oxyntomodulin. We have investigated two GLP-1 receptor allosteric modulators, Novo Nordisk compound 2 and quercetin, and their ability to modify binding and signalling (cAMP formation, intracellular Ca(2+) mobilisation and ERK1/2 phosphorylation) of each of the naturally occurring endogenous peptide agonists, (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v106/%3B%97f%FD%1Cxys SEATTLE-(BUSINESS WIRE)-ZymoGenetics, Inc. (NASDAQ:ZGEN) announced today that James A. Johnson, Executive Vice President and Chief Financial Officer of ZymoGenetics, will present at the Piper Jaffray Europe Conference in London on Wednesday, June 23, 2010 at 11:00 a.m. GMT. A live webcast of the presentation can be accessed by going to: www.zymogenetics.com. The webcast will be archived for 30 days. About ZymoGenetics ZymoGenetics is a biopharmaceutical company focused on the development and commercialization of therapeutic proteins for the treatment of human diseases. The company has developed and is marketing RECOTHROM Thrombin, topical (Recombinant) in the United States. ZymoGenetics (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v106/%3B%97f%FD%13z%7D%7E INTRODUCTION: There is no established laboratory method that can predict the most optimal dose of bypassing agents for treatment of haemophilia A. The objectives of the study was to develop an assay that can a) differentiate between the haemostatic capacity in blood from healthy individuals and severe and moderate haemophilia patients; b) show a dose-response correlation to rFVIIa addition; and c) show dose response differences of rFVIIa addition to plasma samples from non-inhibitor patients of different severity. MATERIALS AND METHODS: Citrated whole blood from 25 haemophilia A patients was used in four thrombelastography (TEG) assays initiated with: 1) kaolin, 2) Tissue Factor (TF, (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v106/%3B%97f%FD%11%7Exs WALTHAM, Mass.-(BUSINESS WIRE)-Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced its Central Coding ¢ application has become the first product to achieve certification by the Uppsala Monitoring Center (UMC). Launched today ( œUppsala Monitoring Centre Launches Software Certification Program for WHO Drug Dictionary Enhanced ), UMC s new certification is designed to help software developers quickly and easily integrate the WHO Drug Dictionary Enhanced. The WHO Drug Dictionary Enhanced is the world s most comprehensive dictionary of medicinal product information and the de facto standard for coding (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v106/%3B%97f%FD%11%7Cx%7F Halle/Saale, June 14, 2010 - Probiodrug AG (Probiodrug), a biotech company developing novel concepts and products for the treatment of neurodegenerative and inflammatory diseases, with a particular focus on Alzheimer's disease, today announced that Dr Claus Braestrup, former President and CEO of H. Lundbeck A/S, has been appointed as a new member of the Supervisory Board and has been elected as its new Chairman. Claus Braestrup will take over from Dr Christoph Schroeder of TVM Capital who will be leaving the board subsequent to the completed handover. œI am very much looking forward to joining Probiodrug as Chairman of the Board. The pioneering research conducted at Probiodrug opens an (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v106/%3B%97f%FD%15%7Dvy We report on a series of 92 surgical procedures (90 patients). It includes 35 orthopaedic procedures (33 patients) and 57 non-orthopaedic procedures (57 patients). The orthopaedic procedures include 27 radiosynovectomies (minor surgery) and eight major orthopaedic procedures. The non-orthopaedic procedures include 52 minor interventions and five major procedures. The average age of patients was 34 years (range: 8-56), and the average follow-up time was 3 years (range: 1-6). Of the 92 surgical procedures, 42 were performed with activated prothrombin complex concentrates [factor eight inhibitor bypassing agent (FEIBA)] and 47 with recombinant-activated factor VIIa (rFVIIa; NovoSeven, Novo (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v106/%3B%97f%FE%12%7Evr The Healthcare Distribution Management Association (HDMA) recognized leading pharmaceutical and consumer product manufacturers with the presentation of 10 Distribution Industry Awards for Notable Achievements in Healthcare (DIANA). The winners were announced at the Association's inaugural Business & Leadership Conference in Orlando, Florida. "The 2010 DIANA winners demonstrate an abiding commitment to innovation and collaboration," said HDMA President and CEO John M. Gray. "These winning companies have shown creativity in introducing new products and services and establishing successful partnerships with their distributor peers in a way that benefits not just the healthcare supply chain (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v106/%3B%97f%FF%13tx%7C SEATTLE-(BUSINESS WIRE)-ZymoGenetics, Inc. (NASDAQ:ZGEN) today announced positive results from a Phase 2 clinical trial in metastatic melanoma with recombinant Interleukin 21 (IL-21) as a single agent. The trial met the primary endpoint of efficacy, as measured by objective response rate or lack of early disease progression. Overall response rate was 23.1%, in evaluable patients, and median progression-free survival was 4.3 months. The results were presented at the American Society of Clinical Oncology meeting. Metastatic melanoma is difficult to treat and has no effective standard of care. We look forward to extending these observations in a randomized Phase 2 study with the selected (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v106/%3B%97f%FF%11uyr Mianowska B, Szadkowska A, Pietrzak I, Zmys?owska A, Wegner O, Tomczonek J, Bodalski J, M?ynarski W. Immunogenicity of different brands of human insulin and rapid-acting insulin analogs in insulin-naïve children with type 1 diabetes. Aims: To determine (i) whether insulin preparations produced by three companies induce the same immune responses in insulin-naïve children with type 1 diabetes (T1DM); (ii) if switching from human insulin to rapid-acting insulin analogs influences this immune response; and (iii) if different insulin brands produce different clinical results during the first 2 yr after T1DM diagnosis. Methods: Insulin antibodies (IA) were measured for 140 patients aged (…) text/html http://www.sciencedaily.com ScienceDaily http://www.lsis.com/goto/v106/%3B%97f%FF%11xzy ScienceDaily (June 3, 2010) Infants with chronic renal failure (CRF) grow slowly, a problem that usually improves with aggressive nutritional therapy. When it doesn't, growth hormone is a safe and effective treatment to promote growth, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN). See Also: Health & Medicine Hormone Disorders Kidney Disease Women's Health Menopause Hair Loss Stem Cells Reference Bone age Growth hormone deficiency Growth hormone Anterior pituitary Early treatment with growth hormone improves growth retardation and bone mineral density without short-term undesirable effects, comments Fernando (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v106/%3B%97f%FF%11%7Fvz Infants with chronic renal failure (CRF) grow slowly, a problem that usually improves with aggressive nutritional therapy. When it doesn't, growth hormone is a safe and effective treatment to promote growth, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN). "Early treatment with growth hormone improves growth retardation and bone mineral density without short-term undesirable effects," comments Fernando Santos, MD, PhD (Hospital Universitario Central de Asturias, Oviedo, Spain). The Spanish-Portuguese multicenter collaborative study included 16 infants with CRF who had continued growth retardation despite nutritional (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v106/%3B%97f%FF%17%7C%7Dr As biology is becoming a data-driven discipline, ontologies become increasingly important for systematically capturing the existing knowledge. This essay discusses current trends and how ontologies can also be used for discovery. |-| PLoS Biol. |-| Jensen LJ, Bork P. |-| Novo Nordisk Foundation Center for Protein Research, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark. text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v106/%3B%97f%FF%15tws DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/718e3b/united_states_diab) has announced the addition of GlobalData's new report "United States Diabetes Care Devices Market Outlook to 2016" to their offering. United States Diabetes Care Devices Market Outlook to 2016 Our new report, US Diabetes Care Devices Market Outlook to 2016 provides key market data on the US diabetes care devices market. The report provides value (USD million), volume (units) and average price (USD) data for each segment and sub-segment within two market categories - Glucose Monitoring and Insulin Delivery. The report also provides company shares and distribution shares data (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v106/%3B%97f%FF%15tv%7B DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/f8bc26/option_and_evaluat) has announced the addition of the "Option and Evaluation Agreements in Pharma and Biotech, 2nd Edition" report to their offering. Option and Evaluation Agreements in Pharma and Biotech, 2nd Edition The Option and Evaluation Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the option and evaluation partnering agreements entered into by the worlds leading biopharma companies. This report provides details of the latest option and evaluation agreements announced in the pharmaceutical and biotechnology sectors. Detailed and (…) text/html http://www.marketwire.com Marketwire http://www.lsis.com/goto/v106/%3B%97g%F6%12zzs NEW YORK, NY-(Marketwire - June 2, 2010) - ExL Pharma's 6th Public Relations and Communications Summit for Pharmaceutical, Biotech and Medical Technology Communicators is taking place this summer at the Pfizer World Headquarters on July 26-27, 2010 in New York, New York. This leading event, which is well attended by communications professionals in pharmaceutical, biotech and medical device companies, features two full days of expert-led presentations, networking opportunities, and interactive sessions. Attendees will gain concrete strategies for success in the marketplace and improved patient outcomes through strengthened communications. *Register before June 11, 2010 to save $200 (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v106/%3B%97g%F6%12%7Fw%7D SEATTLE-(BUSINESS WIRE)-ZymoGenetics, Inc. (NASDAQ:ZGEN) today announced the initiation of the second part of a Phase 2 clinical trial with PEG-Interferon lambda (IL-29) and ribavirin in treatment-naïve patients with chronic hepatitis C virus (HCV) infection. ZymoGenetics is developing the investigational compound PEG-Interferon lambda in collaboration with Bristol-Myers Squibb Company (NYSE:BMY). In part B, we expect to generate a substantial body of data to inform the design of Phase 3 studies, which will assess the potential role of PEG-Interferon lambda in addressing the unmet medical need for a safer, more effective treatment for hepatitis C. œWe ve moved forward into part B of (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v106/%3B%97g%F6%13%7F%7D%7F Reliable application of neutral protamine Hagedorn (NPH) insulin requires previous resuspension of the suspension by tipping over the cartridge 20 times. This procedure is considered annoying by patients. The goal of this investigation was to assess the efficiency of the mixing procedure when performed less frequently than recommended. Neutral protamine Hagedorn insulin cartridges from five different manufacturers (sanofi-aventis, Lilly, Berlin-Chemie, B. Braun, and Novo Nordisk) were emptied with doses of 28 IU in the morning and the evening over 5 days. While the first dose was obtained after a regular resuspension procedure (20x tipping over), the consecutive doses were obtained after (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v106/%3B%97g%F6%10uyx In this issue of Journal of Diabetes Science and Technology, Kaiser and colleagues conducted an investigation to identify variations in the delivered dose of several different isophane insulin (neutral protamine Hagedorn, NPH) brands that use glass and metal bodies ("bullets") to facilitate mixing. Using a strategy where multiple pens from each of five different NPH insulin products (Insuman Basal, sanofi-aventis, three metal bullets; Humulin N, Lilly, one glass bullet; Berlinsulin H Basal, Berlin-Chemie, one glass bullet; Insulin B. Braun Basal, two glass bullets; and Protaphane Penfill, NovoNordisk, one glass bullet) were compared at multiple sampling points and over a range of mixing (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v106/%3B%97g%F6%10x%7Cx Novo Nordisk announced details of the company's cardiovascular outcomes trial for Victoza (liraglutide) which is set to start in the autumn of 2010. The trial named LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) aims to assess and confirm the cardiovascular safety of the company's new once-daily human GLP-1 analogue Victoza and potentially show the ability of Victoza to improve cardiovascular outcomes. The trial also satisfies the new FDA guideline for type 2 diabetes treatments. Because of the scientific opportunity this trial presents, the protocol has been designed in close collaboration with an international expert Steering (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v106/%3B%97g%F6%10%7F%7Fs DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/21fb67/argentina_diabetes) has announced the addition of GlobalData's new report "Argentina Diabetes Care Devices Market Outlook to 2016" to their offering. Argentina Diabetes Care Devices Market Outlook to 2016 Argentina Diabetes Care Devices Market Outlook to 2016 Summary Our medical device report offering, Argentina Diabetes Care Devices Market Outlook to 2016 provides key market data on the Argentina diabetes care devices market. The report provides value (USD million), volume (units) and average price (USD) data for each segment and sub-segment within two market categories - Glucose Monitoring (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v106/%3B%97g%F6%10%7F%7Fz DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/159834/growth_hormone_def) has announced the addition of GlobalData's new report "Growth Hormone Deficiency (GHD) - Pipeline Analysis and Market Forecasts to 2016" to their offering. Growth Hormone Deficiency (GHD) - Pipeline Analysis and Market Forecasts to 2016 Growth Hormone (GH) Deficiency - Drug Pipeline Analysis and Market Forecasts to 2016 is an essential source of information and analysis on the global growth hormone deficiency market. The report identifies the key trends shaping and driving the global growth hormone deficiency market. The report also provides insight on the prevalent (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v106/%3B%97g%F6%10%7Ev%7E DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/fef303/spain_diabetes_car) has announced the addition of GlobalData's new report "Spain Diabetes Care Devices Market Outlook to 2016" to their offering. Spain Diabetes Care Devices Market Outlook to 2016 Spain Diabetes Care Devices Market Outlook to 2016 Summary Our medical device report offering, Spain Diabetes Care Devices Market Outlook to 2016 provides key market data on the Spain diabetes care devices market. The report provides value (USD million), volume (units) and average price (USD) data for each segment and sub-segment within two market categories - Glucose Monitoring and Insulin Delivery. (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v106/%3B%97g%F6%14%7D%7E%7F Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) has approved Norditropin FlexPro (somatropin [rDNA origin] injection), a pre-filled injection pen to be used by children and adults with growth hormone disorders. It will be available in the second quarter. Norditropin FlexPro has a user friendly design which makes it easy to learn and use, and an audible click that confirms that the medication has left the pen. Norditropin FlexPro requires no reconstitution and no loading of cartridges. Norditropin FlexPro is available in 5 mg/1.5 mL, 10 mg/1.5 mL and 15 mg/1.5 mL pens. After first use, the 5 mg/1.5 mL and 10 mg/1.5 mL pens may be left at room (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v106/%3B%97g%F6%15%7Dzy Clearance mechanisms for recombinant activated human FVII (rFVIIa; NovoSeven(R), a heterogeneously glycosylated protein, have yet to be fully elucidated, but may involve the liver. The effects of the gamma-carboxy glutamic acid (Gla) domain and the sialic acid content of the protein on rFVIIa clearance were investigated following intravenous administration of rFVIIa lacking the Gla domain, des(1-44) rFVIIa and asialo-rFVIIa in pharmacokinetic (PK) studies and perfused rat livers. PK parameters for both rFVIIa and des(1-44) rFVIIa had similar biphasic clearance profiles, as well as half-lives ([t(1/2)]=80 and 88 minutes, respectively), while asialo-rFVIIa was cleared quickly (t(1/2)=21 (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v106/%3B%97g%F7%1Dx%7C%7B DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/fedc83/insulin_delivery_s) has announced the addition of the "Insulin Delivery Systems - Global Strategic Business Report" report to their offering. Insulin Delivery Systems - Global Strategic Business Report This report analyzes the worldwide markets for Insulin Delivery Systems in US$ Million by the following major Insulin Delivery Mechanisms - Insulin Syringes, Insulin Pumps (External), and Insulin Pens. The report provides separate comprehensive analytics for US, Europe, and Rest of World. Annual forecasts are provided for each region for the period 2007 through 2015. Also, a six-year historic (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v106/%3B%97g%F7%10%7E%7B%7C DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/52bee2/managed_care_pull) has announced the addition of the "Managed Care Pull - Through Excellence: From Formulary Access to Increased Market Share" report to their offering. Managed Care Pull - Through Excellence: From Formulary Access to Increased Market Share Winning a favorable managed care formulary position can be a Herculean task for pharmaceutical companies today, but successful brand leaders know that position alone doesnt guarantee increased market share. Savvy brand leaders develop and carry out extensive pull-through programs to drive product sales after a formulary win. The analyst (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v106/%3B%97g%F7%10%7Dw%7F DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/2ea526/expanding_a_produc) has announced the addition of the "Expanding a Product Portfolio Without Cannibalizing an Established Brand" report to their offering. Expanding a Product Portfolio Without Cannibalizing an Established Brand Managing multiple products for the same indication is a complex balancing act for bio-pharmaceutical companies today especially those that want to prevent one of their brands from gaining market share at the expense of another. Maximizing the potential of each product requires well-crafted marketing strategies and smart resource allocation plans. Marketers have to make (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v106/%3B%97g%F7%14%7D%7Fz DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/5ad342/netherlands_diabet) has announced the addition of GlobalData's new report "Netherlands Diabetes Care Devices Market Outlook to 2016" to their offering. Netherlands Diabetes Care Devices Market Outlook to 2016 Netherlands Diabetes Care Devices Market Outlook to 2016 Netherlands Diabetes Care Devices Market Outlook to 2016 provides key market data on the Netherlands diabetes care devices market. The report provides value (USD million), volume (units) and average price (USD) data for each segment and sub-segment within two market categories - Glucose Monitoring and Insulin Delivery. The report (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v106/%3B%97g%F7%14%7Czx DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/380241/india_diabetes_car) has announced the addition of GlobalData's new report "India Diabetes Care Devices Market Outlook to 2016" to their offering. India Diabetes Care Devices Market Outlook to 2016 India Diabetes Care Devices Market Outlook to 2016 India Diabetes Care Devices Market Outlook to 2016 provides key market data on the India diabetes care devices market. The report provides value (USD million), volume (units) and average price (USD) data for each segment and sub-segment within two market categories - Glucose Monitoring and Insulin Delivery. The report also provides company shares and (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v106/%3B%97g%F8%10%7By%7F J Thorac Cardiovasc Surg. |-| Christensen MC, Krapf S, Kempel A, von Heymann C. |-| Novo Nordisk A/S, Medical & Science Haemostasis Department, Bagsvaerd, Denmark. text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v106/%3B%97g%F8%17%7Ev%7D DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/9efa40/italy_diabetes_car) has announced the addition of GlobalData's new report "Italy Diabetes Care Devices Market Outlook to 2016" to their offering. Italy Diabetes Care Devices Market Outlook to 2016 Italy Diabetes Care Devices Market Outlook to 2016 Summary Italy Diabetes Care Devices Market Outlook to 2016 provides key market data on the Italy diabetes care devices market. The report provides value (USD million), volume (units) and average price (USD) data for each segment and sub-segment within two market categories - Glucose Monitoring and Insulin Delivery. The report also provides company (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v106/%3B%97g%F8%17%7E%7D%7C DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/b6b2fc/brazil_diabetes_ca) has announced the addition of GlobalData 's new report "Brazil Diabetes Care Devices Market Outlook to 2016" to their offering. Brazil Diabetes Care Devices Market Outlook to 2016 Brazil Diabetes Care Devices Market Outlook to 2016 Summary Brazil Diabetes Care Devices Market Outlook to 2016 provides key market data on the Brazil diabetes care devices market. The report provides value (USD million), volume (units) and average price (USD) data for each segment and sub-segment within two market categories - Glucose Monitoring and Insulin Delivery. The report also provides (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v106/%3B%97g%F8%17%7E%7Dz DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/76582f/mexico_diabetes_ca) has announced the addition of GlobalData's new report "Mexico Diabetes Care Devices Market Outlook to 2016" to their offering. Mexico Diabetes Care Devices Market Outlook to 2016 Mexico Diabetes Care Devices Market Outlook to 2016 Summary Mexico Diabetes Care Devices Market Outlook to 2016 provides key market data on the Mexico diabetes care devices market. The report provides value (USD million), volume (units) and average price (USD) data for each segment and sub-segment within two market categories - Glucose Monitoring and Insulin Delivery. The report also provides (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v106/%3B%97g%F9%1D%7D%7Dx SEATTLE-(BUSINESS WIRE)-ZymoGenetics, Inc. (NASDAQ:ZGEN) announced that final progression-free survival results will be presented from a Phase 2 clinical trial in patients with Stage 4 metastatic melanoma at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on June 5, 2010 in an oral presentation. The open-label multi-center clinical trial evaluated 3 dose regimens of Interleukin 21 (IL-21) in 40 patients with no prior systemic therapy for metastatic melanoma. We selected 30 µg/kg/day as the dose for further investigation and are planning a randomized Phase 2b study with the National Cancer Institute of Canada Clinical Trials Group that will seek to further (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v106/%3B%97g%F9%1D%7D%7C%7C DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/15c32e/united_kingdom_dia) has announced the addition of GlobalData's new report "United Kingdom Diabetes Care Devices Market Outlook to 2016" to their offering. United Kingdom Diabetes Care Devices Market Outlook to 2016 United Kingdom Diabetes Care Devices Market Outlook to 2016 United Kingdom Diabetes Care Devices Market Outlook to 2016 provides key market data on the United Kingdom diabetes care devices market. The report provides value (USD million), volume (units) and average price (USD) data for each segment and sub-segment within two market categories - Glucose Monitoring and Insulin Delivery. (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v106/%3B%97g%F9%1D%7D%7Fz DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/8aa308/australia_diabetes) has announced the addition of GlobalData 's new report "Australia Diabetes Care Devices Market Outlook to 2016" to their offering. Australia Diabetes Care Devices Market Outlook to 2016 Australia Diabetes Care Devices Market Outlook to 2016 provides key market data on the Australia diabetes care devices market. The report provides value (USD million), volume (units) and average price (USD) data for each segment and sub-segment within two market categories - Glucose Monitoring and Insulin Delivery. The report also provides company shares and distribution shares data for each (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v106/%3B%97g%F9%12uy%7B Abstract Objectives: To determine patient ease of use and preference for the Humalog KwikPen * (prefilled insulin lispro [Humalog dagger ] pen, Eli Lilly and Company, Indianapolis, IN, USA) (insulin lispro pen) versus the Next Generation FlexPen double dagger (prefilled insulin aspart [NovoRapid section sign ] pen, Novo Nordisk A/S, Bagsvaerd, Denmark) (insulin aspart pen). Research design and methods: This was a randomized, open-label, 2-period, 8-sequence crossover study in insulin pen-naïve patients with diabetes. Randomized patients (N = 367) received device training, then simulated low- (15 U) and high- (60 U) dose insulin injections with an appliance. Patients rated pens using an (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v106/%3B%97g%F9%16%7C%7Fx Chemical cross-linking coupled with mass spectrometry, an emerging approach for protein topology and interaction studies, has gained increasing interest in the past few years. A number of recent proof-of-principle studies on model proteins or protein complex systems with improved cross-linking strategies have shown great promise. However, the heterogeneity and low abundance of the cross-linked products as well as data complexity continue to pose enormous challenges for large-scale application of cross-linking approaches. A novel mass spectrometry-cleavable cross-linking strategy embodied in Protein Interaction Reporter (PIR) technology, first reported in 2005, was recently successfully (…)